Posted by Michael Wonder on 05 Mar 2024
Zevra Therapeutics provides FDA update on the PDUFA action date for arimoclomol as a treatment for Niemann-Pick disease type C
4 March 2024 - The new PDUFA action date set by the FDA is 21 September 2024.
Zevra Therapeutics today announced the US FDA has extended the review period for the new drug application for arimoclomol, an investigational orally delivered, first in class treatment for Niemann-Pick disease type C.
